Third-generation taxanes are highly effective in pancreatic ductal adenocarcinoma models

Scientists from the Pharmacogenomics laboratory published an experimental article in iScience (Q1 in Multidisciplinary Sciences), in which they describe the efficacy of third-generation taxane derivatives on in vitro and in vivo pancreatic carcinoma cell models.

Long-term cooperation with the team of prof. Iwao Ojima from the USA, who designs and synthesizes the so-called Stony Brook Taxanes (SB-T derivatives), has previously shown that these substances are very effective against a model of resistant ovarian cancer (Šeborová et al. 2022, doi: 10.3389/fphar.2022.971905). In the work now published, very promising results were also reported for pancreatic cancer, which represents one of the least researched malignancies with a very poor clinical prognosis. Colleagues from FN Královské Vinohrady, SZU, 3LF UK, and the Biotechnology Institute of the Academy of Sciences of the Czech Republic participated in this multidisciplinary work. Intensive study of the mechanisms responsible for the observed effects and work on patient avatars, which is the next preclinical phase of research, is now underway in the laboratories.

Link to the article:


Charles University
Faculty of Medicine in Pilsen
Biomedical Center

alej Svobody 1655/76
323 00 Plzeň – Severní Předměstí

T: +420 377 593 810
E: This email address is being protected from spambots. You need JavaScript enabled to view it.


Log in to your account or Create an account